Skip to main content
OpenTrials
Completed

NCT Number: NCT03186976

Reversal of Atrial Substrate to Prevent Atrial Fibrillation Pilot Study

This is a pilot study to assess feasibility to conduct a multi-center, randomized trial to examine the effect of aggressive risk factor control and arrhythmia trigger-based intervention on the atrial substrate, which is involved in the development and maintenance of atrial fibrillation (AF).

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

QE II Health Sciences Centre

Halifax, Nova Scotia, B3H 3A7, Canada

About this study

Atrial fibrillation (AF) is a major health problem, with a prevalence of 0.4-1% of the population. It is associated with a six-fold risk of stroke and a two-fold increase in mortality, the main cardiac reason for death one year after presenting to the emergency department with AF is heart failure. It results in high healthcare costs, recurrent ED visits and hospitalizations. The burden of disability associated with AF has been found to increase by 20% from 1990-2010. AF was also cited as one of the seven causes of death that has been increasing worldwide. Prevention of AF has not been a focus of past treatments and it is well known that elevated body mass index, hypertension, smoking, increased alcohol intake, lack of exercise and sleep apnea are risk factors for AF. There is a lack of randomized, multicenter data proving that a strategy of aggressive risk factor modification will prevent and modify AF.

Upstream therapy for AF has been of considerable interest, and benefit has been demonstrated in primary prevention of AF. Catheter ablation has demonstrated success over current medical therapies for long-term rhythm control, but recurrence remains high, irrespective of ablation strategy. This study is a feasibility study to determine whether a complex and multi-component risk factor modification can be successfully implemented.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patients with symptomatic (CCS-SAF ≥2) recurrent paroxysmal or persistent nonvalvular atrial fibrillation despite rate control, desiring catheter ablation AND
  • one of : BMI>27, BP>140/90 or history of hypertension, alcohol use > recommended limit, current smoking, diabetes with HgA1C>7%, physical inactivity (<150 minutes/week).

(Definitions: Recurrent paroxysmal - at least 4 episodes of symptomatic AF in the prior 6 months, with or without cardioversion; Persistent AF lasting greater than 7 days but less than 3 years; AF must be documented on a Holter, rhythm strip or electrocardiogram within the last 24 months.)

Exclusion criteria

  • Permanent AF (AF lasting > 3 years)
  • Prior catheter ablation for AF
  • Left ventricular ejection fraction <30%
  • Left atrial size > 5.5 cm
  • NYHA IV heart failure
  • Participation in a cardiac rehabilitation program within the last year
  • Currently performing exercise training 150 minutes/week of moderate to vigorous physical activity
  • Unable to exercise
  • Unable to give informed consent
  • Other noncardiovascular medical condition making 1 year survival unlikely

Treatment and study plan

Aggressive Risk Factor Control

Behavioral

1.) Sleep apnea screening, therapy is recommended if apopnea-hypopnea (AHI) index is greater than 15, with a target index of less than 5.

  • Counseling regarding alcohol reduction to 2 drinks/day for men, 1 drink/day for women, no binge drinking (>5 drinks at one setting).
  • Participation in a 12 week structured, home-based exercise program and nutritional counseling. Weight reduction will be emphasized through modification of diet and exercise.
  • An OMRON BP monitor will be supplied to each patient. A target SBP of <140/80 mm/Hg will be targeted.
  • Smoking cessation - through local resources already established at each site 6) Management of diabetes to achieve HgA1c<6.5%

Standard of care

Other

Recommendations based on current guidelines

Primary outcomes

  1. adherence to the risk factor intervention

    Time frame: 6 months

    80% compliance to each of the components: 150 minutes exercise/week, BP target as per CHEP guidelines, alcohol limits, smoking cessation, and sleep apnea therapy, hemoglobin A1C<6.5% at the end of follow up. If 80% of individuals can reach these 80% of the time, the adherence criteria will be met.

Secondary outcomes

  1. Feasibility of recruitment

    Time frame: 6 months

    Recruitment of ≥2.8 patients/center/month over three centers, thereby completing recruitment in 6 months

Sponsors and collaborators

Lead sponsor

Nova Scotia Health Authority

Other

Collaborators

  • Canadian Cardiovascular Society

Registry information

Official study title

Reversal of Atrial Substrate to Prevent Atrial Fibrillation - A Pilot Study

Acronym: RASTA-AF

Important dates

Study start
2018
Primary completion
2019
Study completion
2019
First posted
Jun 14, 2017
Registry last updated
Dec 18, 2019

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.